Myriad 'Aggressively' Eyeing M&A, Companion Dx Deals, Euro Opportunities in FY 2011
August 11, 2010
Myriad 'Aggressively' Eyeing M&A, Companion Dx Deals, Euro Opportunities in FY 2011
Myriad officials said the company is focusing on M&A activity, European expansion, and companion diagnostic development in the coming year.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Myriad Outlines Marketing, Payment Plans to Counter Weak Economy, Raises Test Prices
May 5, 2010 / Pharmacogenomics Reporter - Patents, Regulation, Reimbursement: Myriad Reflects on Impact of Key Events on Future Business
November 3, 2010 / Pharmacogenomics Reporter - Continuing Push to Diversify Offerings, Myriad Licenses Chronix's Early Cancer Detection Technology
May 11, 2011 / Pharmacogenomics Reporter - Missed Opportunity: Would PGx Have Helped Sanofi-Aventis Avoid Phase III Failure for Iniparib?
February 2, 2011 / Pharmacogenomics Reporter - MDxHealth Nets Methylation Biomarker Deal with Pfizer, Partners for PARP Inhibitor
February 2, 2011 / Pharmacogenomics Reporter